According to the IRLSSG guidelines, how are patients with restless legs syndrome (RLS) who are treated with dopaminergic agents monitored and when should multidrug therapy be considered?

Updated: Feb 22, 2017
  • Author: Ali M Bozorg, MD; Chief Editor: Selim R Benbadis, MD  more...
  • Print

Other IRLSSG recommendations include the following:

  • Patients with clinically significant daytime symptoms should be treated with a long-acting agent; multiple daily doses of a short-acting agent can also be tried

  • Considerable caution should be exercised with all dopaminergic agents, with frequent monitoring for loss of efficacy or the development or progression of augmentation

  • Treatment with the combination of a dopamine-receptor agonist and an alpha2-delta calcium-channel ligand should be considered for patients with symptoms that cannot be controlled with low-dose monotherapy of either drug class

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!